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erative diseases is due to the remarkable discovery that
in dominantly inherited -syn substitutions, A53T was
found in at least 12 families with familial PD albeit they
likely share a common ancestor (Polymeropoulos et al.,
1997; Golbe, 1999; Spira et al., 2001).
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clusions, neuroaxonal spheroids, and dystrophic neu-
rites (termed Lewy neurites), were not fully appreciated
until recently, and they are reliably detected by immuno-Summary
cytochemistry with antibodies to -syn (Baba et al.,
1998; Spillantini et al., 1997, 1998). Indeed, using newly-Synucleinopathies are neurodegenerative disorders
developed antibodies to different modified forms ofthat range pathologically from the demise of select
-syn, the neuropathology of -synucleinopathies aregroups of nuclei to pervasive degeneration throughout
being redefined (Duda et al., 2002a). For example, in thethe neuraxis. Although mounting evidence suggests that
Contursi kindred with the A53T -syn mutation, exten--synuclein lesions lead to neurodegeneration, this re-
sive -syn neuritic pathology was detected throughoutmains controversial. To explore this issue, we gener-
the brain, including the limbic system, striatum, andated transgenic mice expressing wild-type and A53T
locus coeruleus. In fact, neuritic pathology is much morehuman -synuclein in CNS neurons. Mice expressing
abundant than perikaryal inclusions, and the substantiamutant, but not wild-type, -synuclein developed a
nigra was not the most severely affected brain nucleisevere and complex motor impairment leading to pa-
(Duda et al., 2002b; Spira et al., 2001). -Syn inclusionsralysis and death. These animals developed age-depen-
also accumulate in oligodendrocytes of patients af-dent intracytoplasmic neuronal-synuclein inclusions
flicted by MSA, but these lesions, termed glial cyto-paralleling disease onset, and the -synuclein inclu-
plasmic inclusions, are largely restricted to this disordersions recapitulated features of human counterparts.
(Duda et al., 2000; Tu et al., 1998). Finally, in situ and inMoreover, immunoelectron microscopy revealed that
vitro biochemical assessments indicate that all -synthe -synuclein inclusions contained 10–16 nm wide
inclusions consist of bundles of 10–25 nm filamentsfibrils similar to human pathological inclusions. These
comprised of polymerized-syn (Baba et al., 1998; Gias-mice demonstrate that A53T -synuclein leads to the
son et al., 1999; Spillantini et al., 1998; Tu et al., 1998).formation of toxic filamentous -synuclein neuronal
PD is the most widely recognized -synucleinopathyinclusions that cause neurodegeneration.
since it is the most common movement disorder, with
a prevalence of 1% at 65 years of age and increasingIntroduction
to 4%–5% by the age of 85 (de Rijk et al., 1997). It is
characterized clinically by bradykinesia, resting tremor,
-Synuclein (-syn) is a small (i.e., 140 amino acids)
rigidity, postural instability, and periods of freezing (Si-
protein predominantly expressed in neurons and con-
muni and Hurtig, 2000). In PD, neuronal -syn pathology
centrated at synaptic terminals (George et al., 1995; is concentrated in brainstem nuclei, including the SNpc
Jakes et al., 1994). Although the function(s) of -syn is and locus coeruleus (Forno, 1996). On the other hand,
ill defined, evidence suggests potential roles in neural DLB and LBVAD are characterized by dementia, parkin-
plasticity and regulation of synaptic vesicle pools (George sonism, hallucinations, and the presence of widespread
et al., 1995; Murphy et al., 2000). Foremost interest in and abundant neuronal -syn inclusions and neurites
-syn surfaced with the recognition that it is the major (McKeith et al., 1996). Although -syn pathologies are
component of pathological intracellular proteinaceous the defining neuropathological hallmarks of -synuclein-
inclusions characteristic of specific neurological disor- opathies, their role in disease pathogenesis and how
ders, including Parkinson’s disease (PD), Lewy body they contribute to impaired cellular function, as well as
(LB) variant of Alzheimer’s disease (LBVAD), dementia brain degeneration, remains unresolved. This is further
with LB (DLB), neurodegeneration with brain iron accu- confounded by the fact that a threonine at amino acid
mulation type-1 (NBIA-1) (formerly known as Hallervor- residue 53 is the normal -syn sequence found in rodent
den-Spatz disease), and multiple system atrophy (MSA) (Hsu et al., 1998). Thus, despite the demonstration that
(Baba et al., 1998; Duda et al., 2000; Galvin et al., 2000; A53T -syn has increased propensity to polymerize in
Spillantini et al., 1997, 1998; Tu et al., 1998). This recogni- vitro (Giasson et al., 1999), these results suggest, but
tion of-syn pathology in a large number of neurodegen- do not unequivocally prove, that aggregates formed by
-syn fibrils are pathogenic. The observation that -syn
polymerization in vitro is concentration dependent (Gi-3 Correspondence: vmylee@mail.med.upenn.edu
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Figure 1. Tg Lines Expressing Human -Syn Driven by the Murine PrP Promoter and Motor Impairment Due to A53T Pathological Mutant
(A) Schematic of the transgene. Wild-type and A53T human -syn cDNAs were cloned into the XhoI site of MoPrP.Xho mammalian expression
vector. The resulting constructs are comprised of the murine PrP promoter, the 5UTR of the PrP gene containing an intron, the human -syn
cDNA, and the 3UTR of the PrP gene (not drawn to scale).
(B) Quantitative Western blot analysis of -Syn overexpression in 3-month-old hemizygous (/) or homozygous (/) Tg mice. Lines M7,
M12, and M20 express wild-type human -syn, while lines M83 and M91 express A53T mutant human -syn. Equal amounts of protein were
loaded on SDS-PAGE gels, and the intensity of the -syn immunoblot band was quantified with 125I-Protein A. The signal was also further
standardized to the levels of NSE (n  3).
(C) Representative Western blots of nitrocellulose membranes probed with SNL-1 (specific for mouse and human -syn), Syn 208 (specific
for human -syn), or anti-NSE antibodies and developed with ECL. The samples were obtained from nTg or homozygous mice from each Tg
line.
(D) Photograph of a 9-month-old homozygous M83 Tg mouse displaying quadriparesis, arched back, and impaired axial rotation to upright
posture.
(E) Onset of motor phenotype in M83 homozygous mice (n  40).
asson et al., 1999; Wood et al., 1999) raises the possibly CNS neurons (Borchelt et al., 1996). Tg lines expressing
wild-type (lines M7, M12, and M20) or mutant A53T (linesthat an increased abundance of -syn may contribute
to the formation of pathological inclusions. To test this M83 and M91) human -syn were bred to homozygosity
(see Experimental Procedures). The levels of -syn ex-hypothesis and assess the consequence of expressing
the A53T -syn in the neurons of intact animals, trans- pression in homozygous Tg mice were determined by
quantitative Western blot (Figure 1B), and representativegenic (Tg) murine lines overexpressing equivalent levels
of wild-type or A53T human -syn were generated. Mice Western blots are depicted in Figure 1C. Neuronal-spe-
cific enolase (NSE) levels were measured and used asexpressing the mutant A53T protein developed a lethal
movement disorder linked to accumulations of patho- a control for equivalent loading of protein extracts. The
anti--syn specific antibody SNL-1, which reacts equallylogical -syn lesions that resembled authentic human
neuronal inclusions. with murine and human -syn (Giasson et al., 2000b),
was used to detect and quantify total -syn. Syn 208,
which is specific for human -syn (Giasson et al., 2000b),Results
was used to detect transgene expression exclusively.
The relative levels of overexpression of-syn, comparedGeneration of Tg Mice that Overexpress
Wild-Type and A53T Human -Syn to endogenous levels, were much higher in the spinal
cord than in the cortex (Figure 1B), but this is due toTo generate Tg mice that express wild-type and mutant
A53T human -syn, the respective cDNAs were cloned the lower amounts of endogenous -syn in the spinal
cord than in the cerebral cortex (see Figure 1C). Theinto the MoPrP.Xho expression plasmid (Figure 1A),
which drives high expression of the transgene in most absolute level of -syn expression within the cortex,
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spinal cord, and cerebellum of each Tg line was similar mice from line M20 as old as 24 months and 14 months,
(Figure 1C). For example, the ratio of total -syn in the respectively, have not displayed any neurological phe-
cortex versus cerebellum and spinal cord was 1.0  notype.
0.4:1.4 0.4:1.0 0.3 for Tg line M7 and 1.0 0.2:1.7
0.4:1.4  0.1 for Tg line M83. Homozygous mice from Histological Characterization of -Syn Pathology
lines M7, M83, and M91 expressed similar levels of Immunostaining for -syn in homozygous mice of lines
-syn, while expression in line M12 was slightly lower M7 and M12, up to the age of 26 months, revealed
in all three regions analyzed biochemically (Figures 1B the normal neuropil staining pattern (data not shown)
and 1C). Homozygous mice from line M20 expressed expected for this protein (Giasson et al., 2001; Jakes et
the highest levels of -syn than any other Tg mouse al., 1994). Similar results were obtained for 24-month-
lines (Figure 1B). The level of overexpression in hemizy- old hemizygous and 14-month-old homozygous mice of
gous Tg mice was more than half the level of homozy- line M20. The same immunostaining pattern also was
gotes. For example, the level of overexpression in the observed in all homozygous Tg mice expressing the
cortex of M20 hemizygotes is 5.6  0.7, compared to A53T mutant protein until the age of 6 months (data not
6.9  0.7 for M20 homozygotes, while it is 3.3  0.5 shown). Furthermore, no differences were detected in
for M83 hemizygotes, compared to 4.6  0.8 for M83 the localization of human or mouse -syn using species-
homozygotes. specific antibodies (data not shown). However, in homo-
Homozygous Tg mice expressing wild-type or A53T zygous A53T mutant -syn animals ranging between 8
mutant human -syn remained healthy without any overt to 16 months of age, -syn inclusions in the somatoden-
phenotype up to the age of 7 months. At this point, mice dritic compartment and dystrophic neurites became
did not have muscle weakness, as determined by their abundant and widely distributed throughout the neu-
ability to stand on a slanted surface. Furthermore, up raxis (Figures 2, 3, 4, and 5). A high density of inclusions
to this age, homozygous mice expressing either wild- was observed in the spinal cord (Figures 2A–2D and 3F),
type (line M7) or A53T (line M83) human -syn did not throughout the brainstem (Figures 2E–2J, 3B–3E, and
exhibit any impaired performance on the rotarod task: 4A), the deep cerebellar nuclei (Figure 2K), deep cerebel-
nTg 306.2 11.0 (n 12), M7 homozygous 316.4 lar white matter, and some regions of the thalamus,
12.0 (n  12), and M83 homozygous  349.3  17.3 such as the medioventral, ventromedial, and paracentral
(n  8). By 8 months of age, a few homozygous mice nuclei (summarized in Figure 3). A gradient of neuritic
expressing A53T -syn began to develop a dramatic pathology was found in the striatum with the densest
motor phenotype. The initial changes included neglect accumulation in the dorsolateral part (Figures 2L and
of grooming, weight loss, and reduced ambulation. 3A), and sparse pathology was found in motor cortex
These changes were followed by severe movement im- (Figure 3). Other regions of the cerebral cortex, the olfac-
pairment with resistance to passive movement and par- tory bulb, and the hippocampus were devoid of -syn
tial paralysis of limbs, accompanied by periods (several pathology. Certain cell populations were completely
seconds) of freezing of a hindlimb. Tremulous motion spared, including the Purkinje cells and granular cells
was observed in some recumbent animals, possibly re-
in the cerebellum and tyrosine hydroxylase (TH)-positive
lated to attempted muscular activity. Paralysis of the
neurons of the substantia nigra. In homozygous M83
extremities usually began at a hindleg, but within a few
and M91 A53T mutant -syn Tg mice, the earliest age
days, all four limbs became affected. At this time, mice
that pathology has been observed is 7 months of age,also were unable to right themselves when placed on
with scant -syn aggregates detected. The same profiletheir sides, and they developed hunched backs (Figure
of -syn inclusions was only detected in hemizygous1D) (see supplemental video clips online at http://www.
Tg mice of line M83 between 22 and 28 months of age,neuron.org/cgi/content/full/34/4/521/DC1). The animals
when animals developed the motor phenotype de-eventually were unable to stand up and support their
scribed above.own body weight. Affected mice became unable to feed
While many perikaryal -syn lesions filled the entirethemselves in a standard cage, but their lifespan could
somatodendritic compartment, some were more distinctbe prolonged for a few days by bottom feeding. Within
structures reminiscent of cortical LBs in humans. These10–21 days of the first signs of disease, animals were
LB-like inclusions were abundant in the raphe nucleisacrificed to prevent suffering. Notably, by contrast to
(Figure 2E) and the pons (Figures 2F and 2G) and lessmany other mouse models of human disease (Cote et
abundant in locus coeruleus (data not shown). Some ofal., 1993; Ishihara et al., 1999; Lee et al., 1994), normal
the inclusions in the locus coeruleus were in TH-positiveand affected -syn Tg mice did not show retraction of
neurons (Figures 4C–4E). -Syn inclusions in neuronaltheir hind limbs when held inverted by the tail.
processes appeared as dystrophic neurites (Figures 2C,To date, all homozygous Tg animals from lines M83
2F, and 2H), reminiscent of LNs in human diseases (Fig-(Figure 1E) and M91 (data not shown) have developed
ures 5A and 5B), as well as larger neuroaxonal spheroidsthe phenotype described above within 16 months of age.
(Figure 2D). Occasional-syn ovoids were also detectedMany hemizygous animals from line M83 also developed
in the sciatic nerve (data not shown).the same phenotype, but the age of onset was between
-Syn inclusions were robustly detected with several22 and 28 months of age. So far, none of the hemizygous
antibodies (i.e., Syn 303, Syn 505, Syn 506, and Syn 514)mice from line M91 up to the age of 28 months have been
raised to oxidized -syn that preferentially recognizeaffected. No neurological phenotype was observed in
pathological -syn in human brain tissue from patientsany of the hemizygous or homozygous Tg mice express-
with synucleinopathies (Duda et al., 2002a). The labelinging wild-type human -syn (lines M7 and M12) up to 28
months of age. Similarly, hemizygous and homozygous of inclusions with a panel of conventional -syn antibod-
Neuron
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Figure 2. Representative -Syn Pathology in Neuronal Cell Bodies and Processes
Immunocytochemistry was performed as described in Experimental Procedures. In the spinal cord, pathology included diffuse perikaryal
inclusions in the ventral horn (A and B), and dystrophic neurites and spheroid-like inclusions in the gray matter (C) or ventral white matter (D),
detected with SNL-4 (A, C, and D) or Syn 303 (B). In addition, LB-like inclusions were found in the raphe nucleus (E) and pons (F and G) and
were stained with Syn 303 (E) and Syn 505 (F and G). Abundant -syn pathology was also seen in neuronal perikarya and processes in the
pontine reticular nuclei (H and I), locus coeruleus (J), and deep cerebellar nuclei (K) stained with Syn 303 (I), Syn 506 (H), or Syn 505 (J and
K). Occasional dystrophic neurites were seen in the striatum (L) stained with Syn 505 (L). Stained tissue sections of homozygous M83 mice
are depicted in (A)–(E), (G) and (H), and (J)–(L), hemizygous M83 mice in (I), and homozygous M91 mice in (F). The age of mice in the micrographs
depicted: 12 months old in (A), (C), (D), and (G)–(H); 14 months old in (B), (E), (J), and (L); 16 months old in (F); 22 months old in (I); and 9
months old in (K).
Bar  40 m in (A), (C), (E)–(H), and (K); 80 m in (B) and (J); 20 m in (D) and (L); 50 m in (I).
ies was variable: robust staining with SNL-4, moderate section and non-Tg mouse  16.7  0.8 neurons/sec-
tion. This finding is consistent with the short time intervalstaining with Syn 202 and LB509, and weak staining
with Syn 211, Syn 102, and Syn 204. These-syn lesions, between appearance of pathological changes and pre-
sentation of phenotype changes. In common with au-especially those in neuronal processes, are strikingly
reminiscent of inclusions found in human synucleinopa- thentic human pathological lesions (Giasson et al.,
2000a), -syn inclusions in mice contained 3-nitro-tyro-thies, including patients with the A53T substitution (see
Figures 5A and 5B), and they do not contain -syn or sine (Figures 5G and 5H), were impregnated with silver
(Figures 5I–5K), and stained with thioflavin S (Figures	-syn, since they were not detected by anti--syn (Syn
207) or anti-	-syn (	-1) antibodies. Likewise, there was 5L and 5M).
also a paucity of staining with phosphorylation-depen-
dent anti-neurofilament (NF) antibodies (e.g., RMO55 Accumulation of Insoluble and Aggregated -Syn
in A53T -Syn Tg Miceand RMO24), but in contrast, another phosphorylation-
dependent anti-NF antibody (RMO32), which was found The spinal cord, cerebellum, and cortex of non-Tg (nTg)
and Tg mice expressing wild-type (M7) and A53T (M83)previously to label many LBs in human PD and DLB
cases (Schmidt et al., 1991), labeled some of the -syn human -syn were sequentially extracted with buffers
with increasing strength of protein solubilization. West-inclusions (Figure 5C). Approximately 10%–25% of
-syn inclusions also demonstrated ubiquitin immuno- ern blotting was used in conjunction with antibodies
specific for mouse and human -syn (SNL-1) or onlyreactivity (Figures 5D and 5E).
Consistent with neuronal injury in affected Tg mice human -syn (LB509), as well as an anti--syn antibody
that preferentially recognizes pathological -syn (Synexpressing A53T-syn, significant astrocytic gliosis was
observed with glial fibrillary acidic protein (GFAP) stain- 303) to detect -syn in these fractions. In nTg mice, the
majority of -syn was recovered in the high-salt (HS)ing (Figure 5F). However, quantitative analysis of motor
spinal neurons did not reveal a significant loss of these and HS/Triton X-100 (T) fractions, but a small amount
could also be observed in the RIPA fraction (Figure 6).cells, even in mice displaying severe motor impairment:
motor impaired M83 Tg mouse  16.5  0.5 neurons/ In M7 mice, the distribution profile was similar to nTg
Neuronal -Synucleinopathy in A53T Mutant Mice
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Furthermore, protein bands that are likely cross-linked
dimers and trimers of -syn were detected in the SDS-
and FA-soluble fractions of the spinal cord of M83 mice
using antibody Syn 303 (Figure 6C).
Ultrastructural Analysis of Pathological Changes
Toluidine blue-stained semi-thin sections from the ven-
tral root of nTg (Figure 7A), M7 Tg mice (Figure 7B), and
M83 Tg mice (Figure 7C) revealed significant axonal
degeneration and an increase in the endoneurial com-
partment in aged mice expressing A53T -syn (Figure
7C). At the ultrastructural level, many degenerating ax-
ons associated with deteriorating myelin could be ob-
served (Figure 7D). However, the initial phase of the
degenerative process appeared to involve axons, since
many severely degenerating axons were still surrounded
by relatively intact myelin sheaths (Figures 7E and 7F).
It appears that following axonal degeneration, myelin
sheath loosens and unravels (Figure 7G), eventually
forming multilamellar myelin debris (Figures 7H and 7I).
Occasionally, these structures were surrounded by
macrophages that appeared to remove debris (data not
shown). Longitudinal (Figure 7J) and axial views (Figure
7K) of axons filled with vacuoles suggested local
blockage of axonal transport. Similarly, disarrayed bun-
dles of NFs were also observed (Figure 7L). Eosin/hema-
toxylin staining of the gastrocnemius muscle revealed
sparse neurogenic muscle atrophy in A53T mice with
impaired movement (data not shown), consistent with
a rapidly progressive axonal neuropathy.
Immunoelectron microscopy of the spinal cord of
Figure 3. Schematic of the Distribution of -Syn Pathology in A53T A53T mice demonstrated the intense and specific label-
-Syn Mice ing of -syn inclusions in axons (Figure 8A). Detachment
Diagrammatic summary of -syn pathology shown as coronal sec- and retraction of the axolemma could be observed in
tions of the mouse neuroaxis at the levels of the pallidum (A), supe- proximity of -syn inclusions (Figure 8B), indicative of
rior colliculi (B), deep cerebellar nuclei (C), inferior colliculi (D), hypo-
axonal degeneration. Aggregation of-syn in the periph-glossal nucleus (E), and cervical spinal cord (F). Large dots represent
ery of the axolemma was also noted in some axonsperikaryal inclusions, while curvilinear markings and small dots cor-
(Figure 8C), a profile seen in human carriers of the A53Trespond to neuritic dystrophy. Abbreviations: AH, anterior horn;
CEREB, cerebellum; CG, central gray matter; CP, caudoputamen mutation (see Discussion). Higher magnification of im-
(striatum); Ctx, neocortex; DC, dorsal columns; DCN, deep cerebel- munolabeled -syn lesions demonstrated that they were
lar nuclei; F, fornix; HIPP, hippocampus; IC, inferior colliculus; IV, predominantly comprised of 10–16 nm fibrils (Figures
fourth ventricle; LC, locus coeruleus; LV, lateral ventricle; Pal, pal-
8D–8F). The specific labeling directly on the fibrils sug-lidum; SC, superior colliculus; SN, substantia nigra; VH, ventral horn;
gests that these polymers are comprised of -syn. Peri-VWM, ventral white matter; X, dorsal motor nucleus of vagus; and
karyal -syn inclusions were also comprised of similarXII, hypoglossal nucleus.
immunolabeled filaments (Figures 9A and 9B). Further-
more, -syn-labeled fibrils are ultrastructurally distinct
mice, but there was an increase in -syn in the RIPA from NFs. A side by side comparison of filaments immu-
fraction of all three anatomical regions analyzed (Figure nolabeled with -syn antibodies and a longitudinal view
6), and there was also a small amount in the SDS-soluble of NFs from the same A53T -syn Tg mouse demon-
fraction of the spinal cord (Figure 6A) and cerebellum strate this difference (Figures 9C and 9D). -Syn immu-
(Figure 6D). It is possible that this -syn in the SDS- nolabeled fibrils are much shorter and irregular (Figure
soluble fractions may correspond to protein aggregates 9C), and they do not have the side arms characteristic
that are not abundant enough to be seen by light micros- of NFs (Figure 9D) (Lee and Cleveland, 1996; Julien and
copy. There was a significant accumulation of RIPA- Mushynski, 1998). To further confirm that inclusions
insoluble (i.e., SDS- or FA-soluble) -syn in the spinal were comprised of filamentous -syn, we isolated -syn
cord (Figure 6A) and cerebellum (Figure 6D) of M83 mice, fibrils biochemically, using a method previously devel-
and a lesser amount was also present in the cortex oped for pathological human brain (Spillantini et al.,
(Figure 6G) (for quantitation, see supplemental data on- 1998). Filaments were clearly immunolabeled with anti-
line at http://www.neuron.org/cgi/content/full/34/4/ bodies to -syn in preparations from the cerebellum
521/DC1). RIPA-insoluble -syn in M83 mice was com- (Figure 9E), spinal cord (Figure 9F), and pons (Figures
prised of human A53T mutant -syn (Figures 6B, 6E, 9G and 9H) from A53T -syn Tg mice. Furthermore,
and 6H). Aggregated -syn that did not enter the resolv- isolated -syn filaments were not labeled with antibod-
ing gels was also detected in the HS- and SDS-soluble ies to NFs in double-labeling experiments (data not
shown).fractions of the spinal cord of M83 mice (Figures 6A–6C).
Neuron
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Figure 4. Characterization of -Syn Inclu-
sions in A53T -Syn Mice
Low-power light microscopy of -syn inclu-
sions in the pons of a 12-month-old homozy-
gous M83 mouse immunolabeled with anti-
body Syn 505 (A). Immunofluorescence
microscopy of spinal cord stained with Syn
303 in a 12-month-old homozygous M83
mouse reveals abundant inclusions in neu-
ronal cell bodies and processes (B). A section
of the locus coeruleus from a 12-month-old
homozygous M83 mouse were double-
labeled with anti-TH ([C], green) and Syn 505
([D], red) antibodies. Syn 505 staining reveals
that some of TH-expressing cells in the locus
coeruleus also contain -syn aggregates
(composite image in [E]).
Scale  140 m in (A); 80 m in (B); 40 m
in (C)–(E).
Discussion that coincides with the formation of -syn aggregates.
These finding represent compelling evidence for the det-
rimental role of -syn inclusion formation, a position thatThe dramatic behavioral phenotype associated with the
formation of -syn inclusions in mice expressing A53T is still controversial. Furthermore, the -syn inclusions
in these mice recapitulate all aspects of the typical char-human -syn represent an excellent model of -synu-
cleinopathies. This model has a robust phenotype leading acteristics of human inclusions, and similar to humans,
these mice display significant -syn aggregation in bothto the demise of the animals and neuronal dysfunction
Figure 5. Properties of Inclusion in A53T -Syn Mice
For comparison of the inclusions in the mice and human-expressing A53T -syn, we have included micrographs demonstrating abundant
LNs and neuroaxonal spheroids detected with Syn 303 in the entorhinal cortex of a patient of the Contursi kindred harboring the A53T -syn
substitution (A and B). In mice expressing A53T human -syn, some inclusions (exemplified here in spinal cord) were also labeled with anti-
NF antibody RMO32 (C) and with anti-ubiquitin antibodies (D and E). Also depicted in the spinal cord, GFAP immunoreactivity revealed
astrocytic gliosis (F). The presence of 3-nitro-tyrosine in -syn inclusions in the pons was detected with nSyn 823 (G and H). -Syn pathology
was visualized by silver (I–K) and thioflavin S staining (L and M). Arrows were placed to highlight pathological inclusions. Stained tissue
sections of 12-month-old homozygous M83 mice are depicted in (C)–(M).
Bar  40 m in (A), (E), (G), (H), (K), and (L); 80 m in (F); 20 nm in (B), (D), (J), and (M); 50 m in (C); and 33 m in (I).
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Figure 6. Accumulation of Insoluble and Aggregated -Syn in Mice Expressing A53T Mutant -Syn
Samples of spinal cord (A–C), cerebellum (D–F), and neocortex (G–I) from 9-month-old nTg, homozygous M7 Tg (M7), and homozygous M83
Tg (M83) mice were sequentially extracted, as described in Experimental Procedures. HS-, HS/T-, RIPA-, SDS-, and formic acid (FA)-soluble
fractions were analyzed by Western blotting using antibody SNL-1 (-syn specific), antibody LB509 (human -syn specific), and antibody Syn
303 (preferentially recognizes pathological -syn). The positions of molecular mass markers are depicted on the left. The arrow indicates the
resolving and stacking gel interface.
neuronal cell bodies and processes. Moreover, the -syn pathology in autopsy tissue revealed that it is
significantly more widespread throughout the neuraxisspecificity of the pathological changes in mice express-
ing A53T human -syn, in contrast to the lack thereof in than in PD (Spira et al., 2001; Duda et al. 2002b). As in
idiopathic PD, LBs were observed in midbrain nuclei;mice expressing the wild-type protein, provides further
credence to the notion that this amino acid substitution however, diffusely distributed neuritic pathology was
the prominent finding. Similarly, aggregation of -syn inleads to neurodegeneration by promoting the formation
of filamentous inclusions. neuronal processes was a major feature of Tg mice from
lines M83 and M91 (see Figures 2, 3, 4A, and 4B). Also,The A53T -syn mutation in humans is generally de-
scribed as resulting in clinical PD with a notably early the profile of aggregated -syn at the periphery of axo-
lemma in Tg mice (Figure 8C) is akin to inclusions ob-age of onset (45 years of age) (Golbe et al., 1996; Spira
et al., 2001). However, the clinical presentation includes served in a patient with the A53T mutation (Duda et al.,
2002b).several features (such as dementia, prominent myoclo-
nus, and urinary incontinence) that are not characteristic Several other Tg mouse models expressing wild-type
and mutant -syn have been described recently, butof PD, especially considering the young age of the indi-
viduals (Golbe et al., 1996; Spira et al., 2001). Consistent these models neither revealed the differences between
wild-type and mutant -syn nor did they fully recapitu-with these findings, examination of the distribution of
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Figure 7. Wallerian Degeneration in Ventral
Roots of A53T -Syn Mice
Representative semi-thin sections of L5 ven-
tral roots from 12-month-old nTg (A), homo-
zygous M7 Tg (B), and homozygous M83 Tg
(C) mice. Note the extensive axonal degener-
ation and increased endoneurial space in
M83 mice. Ultrastructural analysis of ventral
roots by transmission electron microscopy
reveals abundant axonal degeneration char-
acterized by axonal atrophy and demyelin-
ation (D). Axonal degeneration without dis-
ruption of the contiguous myelin sheath (E
and F). Axonal atrophy accompanied by de-
generation of contiguous myelin resulting in
loosening of myelin wraps (G) and the forma-
tion of multilamellar bodies (H and I). Aberrant
axonal swellings containing accumulations of
vacuoles, vesicles, and mitochondria (J and
K) and bundles of disarrayed NFs (L) in the
ventral root of homozygous M83 Tg mice.
Bar  30 m in (A)–(C); 4 m in (D); 1 m in
(E) and (K); 2 m in (F), (G), and (L); 1.5 m
in (H) and (J); and 3 m in (I).
late the characteristics of human -syn pathology (Kahle pairment (
3 weeks of age), as measured by rotating
rod performance, and this phenotype was associatedet al., 2000; van der Putten et al., 2000). The comparison
of these different models is complicated by the use of with axonal degeneration in the spinal root and muscle
denervation (van der Putten et al., 2000). A subset ofdifferent promoters, which have varied expression in
specific neuronal populations. This caveat notwith- -syn inclusions in these mice were argyrophillic and
immunoreactive for ubiquitin, but they lacked the fila-standing, other groups have used the human platelet-
derived growth factor- (PDGF-) and the murine Thy-1 mentous characteristic of authentic human -syn inclu-
sions. On the other hand, expression of wild-type orpromoter to express human -syn in mice. In the study
utilizing the PDGF- promoter, expression of wild-type mutant human -syn in Drosophila results in the forma-
tion of filamentous -syn inclusions concomitant withprotein resulted in the formation of amorphous, nonfila-
mentous -syn aggregates associated with impairment the demise of dorsomedial dopaminergic neurons and
impairment of locomotor function (Feany and Bender,of motor function and reduction in striatal TH terminals
(Masliah et al., 2000). A subset of -syn inclusions also 2000).
Our Tg mouse model has many similarities with humancontained ubiquitin, which is characteristic of authentic
human inclusions (Love and Nicoll, 1992). However, un- neuronal -synucleinopathies (especially familial PD)
due to the A53T -syn mutation. Foremost, PrP-drivenexpectedly (and at odds with reported human synuclein-
opathies), a significant portion of these inclusions were expression of human A53T -syn results in a mid-to-
late onset neurodegenerative disorder that coincideslocated in the nucleus.
Expression of wild-type and A53T or A30P mutant with the accumulation of filamentous -syn cytoplasmic
inclusions throughout the neuraxis, similar to patients-syn in Tg mice driven by the Thy-1 promoter results in
the appearance of perikaryal and neuritic accumulations with the A53T mutation. No -syn pathology was de-
tected in young animals (6 months) expressing A53Tbut without notable differences between wild-type and
mutant proteins (Kahle et al., 2000; van der Putten et human-syn, and these animals did not present an overt
neurological impairment. The onset of this disease isal., 2000). In one study, mice expressing wild-type or
A53T mutant -syn developed an early onset motor im- heralded by the appearance of sparse pathology without
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Figure 8. Immunoelectron Microscopy of -Syn Inclusion in the Spinal Cord of M83 Tg Mice
(A) Immunolabeling of axonal -syn aggregates with antibody Syn 303 demonstrates the specific labeling of a filamentous component.
(B) -Syn accumulation is seen in an atrophied axon where the axolemma is detached from the myelin.
(C) Intense accumulation of -syn also can occur at the periphery of the axolemma, as indicated by the arrow. “m” refers to the myelin sheath.
(D–F) Higher magnification of -syn inclusions shows the labeling of 10-16 nm wide fibrils.
Bar  1.3 m in (A) and (C); 1.7 m in (B); 400 nm in (D); 600 nm in (E); and 300 nm in (F).
clinical manifestations similar to humans (Forno, 1996). ventral root may contribute to motor impairment. Yet, the
complex changes exhibited by mice expressing A53TThe precise mechanism to account for the selective
vulnerability of neurons affected in these mice remains human -syn suggest dysfunction in other neuronal sys-
tems. Furthermore, the lack of clasping behavior, char-unclear. However, the presence of -syn pathology in
motor neurons of the ventral horn and axons in the acteristic of other mouse models involving the demise
Figure 9. Inclusions in A53T -Syn Tg Mice
Are Comprised of Filamentous -Syn
Immunoelectron microscopy of perikaryal in-
clusions in the deep cerebellar nuclei (A) of
an 11-month-old homozygous M83 Tg mouse
(Nu  nucleus). Higher magnification of the
latter inclusion depicting immunolabeled fila-
ments (B). Immunoelectron microscopy of a
filamentous -syn inclusion in the spinal cord
of a 10-month-old homozygous M83 Tg
mouse (C) and a micrograph depicting a lon-
gitudinal view of neurofilaments in the same
animal (D). Note that the presence of side
arms protruding from NFs are highlighted by
arrow heads. Isolated -syn filaments ex-
tracted form the cerebellum (E), spinal cord
(F), and pons (G and H) of a 9-month-old ho-
mozygous M83 Tg mouse are labeled with
antibodies Syn 303 (E–G) or LB509 (H). The
dark particles are 10 nm colloidal gold conju-
gated to the anti-mouse antibody (see Experi-
mental Procedures).
Bar  4.9 m in (A); 250 nm in (B); 190 nm in
(C) and (D); 50 nm in (E), (F), and (H); and 55
nm in (G).
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of motor neurons (Cote et al., 1993; Ishihara et al., 1999; ent dimers/trimers in A53T mice suggest that -syn may
be cross-linked by covalent modifications that couldLee et al., 1994) suggests a different mechanism. The
rapid and catastrophic presentation of the phenotype involve oxidative modification. (5) A significant number
of -syn inclusions in A53T mice, like authentic -synindicates either the synchronized formation of patholog-
ical lesions or the accumulation of neuronal injury that inclusions in human neurodegenerative diseases, are
detected by Gallyas silver staining and amyloid-bindingeventually surpasses a threshold for behavioral manifes-
tations. In striking contrast to Tg mice expressing A53T dyes (such as thioflavin S). (6) Finally, just like -syn
filaments found in LBs and Lewy neurites in human sy--syn, mice expressing wild-type human -syn did not
develop any form of aberrant -syn accumulations or nucleinopathies, -syn filaments from A53T mice are
comprised of 10–16 nm fibrils that are directly andneurological defects, although it remains a possibility
that older M20 mice may eventually be affected. intensely labeled with antibodies to -syn.
The most likely explanation for the neurotoxicity ofThe location of pathological lesions in A53T mice does
not completely correspond with human disorders, but the A53T -syn mutation resides in altered biophysical
properties, since this mutation increases the propensityit shares many similarities. Pathology was very abundant
in the brain stem and in several nuclei affected in PD of -syn to polymerize into fibrils in vitro, when com-
pared to wild-type -syn (Giasson et al., 1999). The for-and DLB, such as the locus coeruleus and the raphe
nucleus. Interestingly, the presence of striatal pathology mation of -syn fibrils eventually leads to the formation
of toxic neuronal inclusions. The depletion of functionalcoincides with human diseases (Shoji et al., 2000; Duda,
et al., 2002a). Furthermore, the abundance of neuritic -syn due to sequestration in inclusions is not a factor
in the pathogenicity, since ablation of -syn in mice bypathology is consistent with these disorders, and the
formation of large axonal inclusions is reminiscent of gene targeting shows only mild electrophysiological and
behavioral changes, but not an overt phenotype (Abelio-human -syn neuroaxonal spheroids, which are charac-
teristic of NBIA-1. An obvious difference is the paucity vich et al., 2000). Thus, -syn inclusions likely act as
physical obstacles impeding the physiological move-of pathology in TH-expressing neurons of the substantia
nigra. In mice, it does not appear that these neurons ment of organelles and smaller cytoplasmic metabolites.
This notion is supported by the changes observed in thedisplay the same selective vulnerability as in humans.
A recent report using the TH promoter to express wild- axons of A53T Tg mice that include axonal enlargements
filled with vacuoles or disorganized NF networks. Thetype and mutant -syn selectively in these neurons did
not result in the formation of inclusions (Matsuoka et ultrastructural changes observed are consistent with a
primary neuronal degeneration with subsequent myelinal., 2001). It is not clear why these neurons would have
different cross-species properties, but the lack of neuro- injury.
It can be surmised that the A53T mutation is pathologi-melanin formation in mice could be a determinant. Fur-
thermore, this population of neurons may be protected cal due to an increased propensity to form filamentous
inclusions. An additional pathogenic insult seems to befrom the formation of inclusions induced by Tg expres-
sion due to intrinsic protective mechanisms necessary required to induce the formation of similar lesions from
wild-type -syn, since simple overexpression of wild-to compensate for their normal heightened exposure to
oxidative damage. type -syn within the timeframe of these experiments
is insufficient. One possibility is suggested by a recentThe immunological, histological, biochemical, and ul-
trastructural properties of inclusions in mice carrying study demonstrating that the presence of extracellular
-amyloid deposits increases the abundance and pro-human A53T -syn closely resemble authentic human
pathological inclusions. (1) -Syn inclusions in these Tg motes the fibrillization of -syn aggregates in PDGF-
Tg mice (Masliah et al., 2001). Experimental cell culturemice share the characteristic immunological properties
of authentic human lesions. They are strongly labeled models suggest that oxidation or nitrative damage can
result in the formation of -syn aggregates (Paxinou etwith antibodies that preferentially mark human patho-
logical inclusions (i.e., Syn 303, Syn 505, Syn 506, and al., 2001), and LB-like inclusions can be induced in rats
treated with rotenone (an inhibitor of the mitochondrialSyn 514). (2) A subset of inclusions are selectively la-
beled with a phosphorylation-dependent anti-NFM anti- complex I), presumably due to increased oxidative
stress (Betarbet et al., 2000). The mechanism involvedbody (RMO32), which is exceptional at labeling most
LBs (Schmidt et al., 1991), but not with other phosphory- in the formation of inclusions from wild-type human
-syn is still unclear, but the evidence that filamentouslation-dependent NF antibodies. (3) A proportion of in-
clusions are modified by ubiquitin or 3-nitro-tyrosine. -syn inclusions can be the major determinant of a num-
ber of neurodegenerative disorders underscores the im-3-Nitro-tyrosine was only detected in a small number of
inclusions, indicating that the modification is likely not portance of elucidating these pathways. This premise
is supported by the findings herein and several patho-required for the formation of inclusions in Tg mice. How-
ever, it is possible that other nitrative modifications, logical studies correlating LB density with severity of
dementia in patients (Hurtig et al., 2000; Mattila et al.,especially o-o dityrosine cross-linking that occurs in
concert with nitration and could be involved in the stabi- 2000).
The PrP mice expressing wild-type human -syn willlization of some aggregates. (4) The presence of deter-
gent-insoluble, as well as high molecular-mass, -syn be useful in establishing putative cellular insights that
promote formation of intracytoplasmic lesions. Further-aggregates that do not enter the SDS-PAGE resolving
gel is also similar to the properties of -syn inclusions more, the A53T mice may be valuable in screening for
potential therapeutics that inhibit or reverse -syn ag-in human diseases (Baba et al., 1998; Dickson et al.,
1999; Duda et al., 2000; Galvin et al., 2000). The accumu- gregate formation. It is uncertain if the formation of-syn
inclusions is reversible, but this concept has been dem-lation of these high molecular-mass species and appar-
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Immunocytochemistryonstrated in other Tg models of neurodegenerative dis-
Mice, anesthetized with an intraperitoneal overdose injection of xy-ease associated with proteinaceous inclusions (Schenk
lazine and ketamine, were perfused with phosphate-buffered salineet al., 1999; Yamamoto et al., 2000) leading to novel
(PBS), followed by 70% ethanol/150 mM NaCl or PBS buffered for-
therapeutic strategies. malin. Following surgical removal of brain and spinal cord, tissue
was fixed for another 24 hr in the respective fixatives. Samples were
Experimental Procedures dehydrated through a series of graded ethanol solutions to xylene
at room temperature, infiltrated with paraffin at 60C as described
Generation of -Syn Tg Mice in Trojanowski et al. (1989), and cut into serial 6 m sections. Immu-
Wild-type human -syn cDNA (Jakes et al., 1994) and the same nocytochemistry was conducted as previously described (Duda et
cDNA harboring the A53T mutation were cloned into the MoPrP.Xho al., 2000).
expression vector (Borchelt et al., 1996) at the XhoI restriction site.
The 14 kb NotI linear fragments containing the -syn cDNA and Double-Labeling Immunofluorescence
the mouse prion protein (PrP) gene promoter, together with its 5 Double-labeling immunofluorescence studies were performed by
untranslated region (UTR) containing an intron and its 3 untrans- incubating sections with Syn 505 and anti-TH antibodies. Following
lated sequences (Figure 1A), were used as the transgene to create extensive washes, sections were labeled using Alexa Fluor 488
-syn Tg mice on a C57Bl/C3H background. The Tg DNA was mi- (green) and 594 (red) conjugated secondary antibodies (Molecular
croinjected into C57Bl/C3H mouse eggs as a service provided by Probes, Eugene, OR) and covered with Vectashield-DAPI mounting
the Transgenic and Chimeric Mouse Facility of the University of medium (Vector Laboratories, Burlingame, CA).
Pennsylvania. Genomic DNA samples were isolated from mouse
tails with the Puregene DNA isolation kit (Gentra Systems, Minneap- Spinal Cord Neuronal Counting
olis, MN). Potential founders were identified by Southern blot analy- The L2–L3 spinal cord segments of Tg and nTg mice were formalin
sis with a 32P-labeled oligonucleotide-primed -syn DNA probe. Sta- fixed and paraffin embedded. The entire spinal cord segments were
ble Tg lines carrying the wild-type (lines M7, M12, and M20) or cut in 12 M thick sections, which were stained with cresyl violet.
mutant A53T (lines M83 and M91) human -syn constructs were Motor neurons in Rexed’s laminae IX of the L2 and L3 spinal levels
established, and Tg and wild-type offspring were identified by were counted by two observers.
Southern blot analysis of tail DNA. Homozygous Tg lineages were
identified by quantitative Southern blot analysis and verified by
Sequential Biochemical Fractionation
backcrossing.
Cortex, cerebellum, and spinal cord from 9-month-old mice were
dissected, weighed, and homogenized in 3 ml/g of HS buffer (50
Rotarod Task mM Tris [pH 7.5], 750 mM NaCl, 5 mM EDTA, and a cocktail of
This task for locomotor function was conducted using a Rota-Rod protease inhibitors). The samples were sedimented at 100,000  g
treadmill Model 7650 (Ugo Basile, Comerio, Italy), set with accelerat- for 20 min. Pellets were reextracted with HS buffer, followed by two
ing revolution (4–40 revolutions per min) over a 5 min period. Mice sequential extractions with 3 ml/g of HS buffer containing 1% Triton
were given three trails a day for 3 consecutive days. X-100 (HS/T fraction). The pellets were homogenized in 500 l of
HS buffer/1 M sucrose, and, after centrifugation, the floating myelin
was discarded. The pellets were extracted with 2 ml/g of RIPA (50Antibodies
mM Tris [pH 8.0], 150 mM NaCl, 5 mM EDTA, 1% NP40, 0.5% sodiumSNL-1 and SNL-4 are rabbit antibodies raised to synthetic peptides
deoxycholate, and 0.1% SDS) and sedimented at 100,000  g forcorresponding to amino acids 2–12 and 104–119 in -syn, respec-
20 min. Half of each pelleted sample was extracted with 1 ml/g SDStively (Giasson et al., 2000b). Syn 211, Syn 204, Syn 208, and LB
sample buffer (SDS fraction) by sonication and heated to 100C for509 are mouse monoclonal antibodies specific for human -syn,
10 min in or 70% formic acid (FA fraction) by sonication. FA waswhile Syn 102 and Syn 202 are mouse monoclonal antibodies that
removed by lyophilization, and the dried material was resuspendedbind to both - and -syn (Giasson et al., 2000b). Syn 207 is a -syn-
in 1 ml/g of SDS-sample buffer by heating to 100C for 10 min. 5 lspecific mouse monoclonal antibody (Giasson et al., 2000b), and
of each fraction was loaded on separate lanes of 12% polyacryl-	-1 is a 	-syn-specific rabbit antibody (Giasson et al., 2001). Syn
amide gels, and the distribution of -syn was determined by Western303, Syn 505, Syn 506, and Syn 514 are mouse monoclonal antibod-
blotting analysis.ies raised to oxidized human -synuclein, as previously described
(Giasson et al., 2000a). Although these antibodies do not recognize
a specific oxidation modification, they preferentially recognize Conventional and Immunoelectron Microscopy
pathological -syn inclusions (Duda et al., 2002a; B.I.G., unpub- For direct electron microscopy, mice were deeply anesthetized and
lished data). nSyn 823 is a nitration-specific antibody raised to ni- sacrificed by intracardiac perfusion with 0.1 M cacodylate buffer
trated -syn (Giasson et al., 2000a). Murine monoclonal antibodies (pH 7.4), followed by 4% paraformaldehyde/2% glutaraldehyde in
RMO32 and RMO55 are specific for phosphorylated NF midsize 0.1 M cacodylate (pH 7.4). The L5 segments of the spinal cord and
subunit (NFM), and RMO24 is specific for phosphorylated NF heavy L5 ventral roots were removed and further fixed for 18 hr. Tissue
subunit (NFH) (Schmidt et al., 1991). Antibody 17026 is tau-specific was postfixed with 2% osmium tetraoxide for 1 hr, dehydrated with
rabbit polyclonal antibody and PHF-1 is mouse monoclonal anti- graded ethanol solutions, and embedded in Epon.
body-specific for a phosphorylation epitope in tau. Anti-NSE (Polys- Mice prepared for pre-embedding immunoelectron microscopy
ciences, Inc., Warrington, PA), anti-GFAP (DAKO, Glostrio, Den- were perfused with 0.1 M cacodylate buffer (pH 7.4), followed by
mark), and anti-TH (Pelfreeze, Rogers, AK) are rabbit polyclonal 2% paraformaldehyde/0.5% glutarldehyde in 0.1 M cacodylate (pH
antibodies. Anti-ubiquitin (MAB1510) was purchased from Chemi- 7.4). The tissue was further fixed for 12 hr, washed with PBS, cut
con International, Inc. (Temecula, CA). into 50 M sections, and reacted with 0.1% sodium borohydrate in
PBS for 10 min. Following extensive blocking, sections were labeled
with antibody Syn 303 and sequentially incubated with a biotinylatedGel Electrophoresis and Western Blotting
goat anti-mouse antibody and ABC reagents. Following the reactionMouse tissues were dissected and disrupted in 2% SDS, 50 mM
with DAB, tissue sections were further developed with silver methe-Tris (pH 6.8) by sonication and heated to 100C for 10 min. Protein
namine, as previously described (Rodriguez et al., 1984). Sectionsconcentrations were determined using the biocinchoninic acid (BCA)
were postfixed with 1.5% glutaraldehyde and 1% osmium tetraox-assay (Pierce, Rockford, IL). Western blot analysis was performed
ide, and, following dehydration in graded ethanol, they were embed-as previously described (Giasson et al., 1999). Quantitative Western
ded in Epon.blotting was performed using 125I-labeled protein A (NEN) as second-
ary antibody. NSE was included as an internal standard to monitor
loading errors. The membranes were dried and exposed to a Phos- Isolation of Dispersed -Syn Filament
-Syn filaments were extracted from the pons, cerebellum, or spinalphorImager plate. The radioactive signal was quantified using Im-
ageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA). cord of 9-month-old motor-impaired M83 mice using a method pre-
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viously described for human tissue (Spillantini et al., 1998). Briefly, Feany, M.B., and Bender, W.W. (2000). A Drosophila model of Parkin-
son’s disease. Nature 404, 394–398.tissue was homogenized in 50 mM Tris (pH 7.4), 750 mM NaCl, 2
mM EGTA, and 10% sucrose. After centrifugation at 14,000  g for Forno, L.S. (1996). Neuropathology of Parkinson’s disease. J. Neuro-
20 min, the supernatant was incubated with 1% sarcosyl for 30 min. pathol. Exp. Neurol. 55, 259–272.
The solution was centrifuged at 100,000  g for 1 hr, and the re-
Galvin, J.E., Giasson, B., Hurtig, H.I., Lee, V.M.-Y., and Trojanowski,
sulting pellet was resuspended in 50 mM Tris (pH 7.4). Aliquots of
J.Q. (2000). Neurodegeneration with brain iron accumulation, type
the dispersed filaments were applied onto carbon-coated 300-mesh
1 is characterized by -, - and 	-synuclein neuropathology. Am.
copper grids. Grids were blocked with 1% bovine serum albumin in
J. Pathol. 157, 361–368.
PBS and filaments were immunolabeled with anti--syn antibodies,
George, J.M., Jin, H., Woods, W.S., and Clayton, D.F. (1995). Charac-followed by a goat anti-mouse antibody secondary conjugated to
terization of a novel protein regulated during the critical period for10 nm gold. Fibrils were visualized by negative staining with 1%
song learning in the zebra finch. Neuron 15, 361–372.uranyl acetate.
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